Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 30/04/2020
• Auteurs : Nathalie ChazalHugues de RocquignyPhilippe RousselSerge BouazizFrançoise Barré-SinoussiJean-François DelfraissyJean-Luc Darlix
• Organismes : Institut de Recherche en Infectiologie de Montpellier Morphogénèse et antigénicité du VIH, des Virus des Hépatites et Emergents Faculté de Médecine Henri Warembourg - Université de Lille Cibles Thérapeutiques et conception de médicaments Institut Pasteur [Paris] Comité consultatif national d’éthique pour les sciences de la vie et de la santé Laboratoire de Bioimagerie et Pathologies
• Publié dans Retrovirology le 28/10/2020

---

Fichiers liés : s12977-020-00518-0.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 29/04/2020
• Auteurs : Clementine LevyGuillaume LassaillyMehdi El AmraniFlavien VincentCedric DelhayeThibault MeuriceEmmanuel BoleslawskiGuillaume Y. MilletMassih NingarhariStéphanie TruantAlexandre LouvetPhilippe MathurinGilles LebuffeFrancois-Rene PruvotSebastien Dharancy
• Organismes : CIC CHU ( Lille)/inserm Lille Inflammation Research International Center - U 995 Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - UAR 3290 Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 Institut Coeur Poumon [CHU Lille] Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Régional Universitaire [CHU Lille] Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Lille Inflammation Research International Center - U 995 Lille Inflammation Research International Center - U 995 Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 Centre Hospitalier Régional Universitaire [CHU Lille] Lille Inflammation Research International Center - U 995
• Publié dans American Journal of Transplantation le 26/10/2020

---

Résumé : Severe aortic stenosis is a widespread valve disease, constituting a contraindication to organ transplantation due to cardiovascular morbidity and projected mortality. Mortality after conventional surgical aortic valve replacement in cirrhotic patients depends upon the Child-Pugh class. In the past few years, transcatheter aortic valve replacement has progressively become the treatment of choice for high-risk patients with severe aortic stenosis. Here, we report the cases of 3 cirrhotic patients who became eligible for liver transplantation after successful transcatheter aortic valve replacement as bridge therapy.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 28/04/2020
• Auteurs : Vincent LeclèrePierre CarpentierJean-Philippe ChancelierArnaud LenoirFrançois Pacaud
• Organismes : Centre d'Enseignement et de Recherche en Mathématiques et Calcul Scientifique Optimisation et commande Centre d'Enseignement et de Recherche en Mathématiques et Calcul Scientifique EDF R&D Centre d'Enseignement et de Recherche en Mathématiques et Calcul Scientifique ITE EFFICACITY
• Publié dans SIAM Journal on Optimization le 22/10/2020

---

Résumé : The Stochastic Dual Dynamic Programming (SDDP) algorithm has become one of the main tools to address convex multistage stochastic optimal control problem. Recently a large amount of work has been devoted to improve the convergence speed of the algorithm through cut-selection and regularization, or to extend the field of applications to non-linear, integer or risk-averse problems. However one of the main downside of the algorithm remains the difficulty to give an upper bound of the optimal value, usually estimated through Monte Carlo methods and therefore difficult to use in the algorithm stopping criterion. In this paper we present a dual SDDP algorithm that yields a converging exact upper bound for the optimal value of the optimization problem. Incidently we show how to compute an alternative control policy based on an inner approximation of Bellman value functions instead of the outer approximation given by the standard SDDP algorithm. We illustrate the approach on an energy production problem involving zones of production and transportation links between the zones. The numerical experiments we carry out on this example show the effectiveness of the method.

---

Fichiers liés : optim-online1.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 27/04/2020
• Auteurs : Thierry WirthMarine BergotJean-Philippe RasigadeBruno PichonMaxime BarbierPatricia Martins-SimoesLaurent JacobRachel PikePierre TissieresJean-Charles PicaudAngela KearnsPhilip SupplyMarine ButinFrédéric LaurentThe International Consortium For Staphylococcus Capitis Neonatal SepsisThe Esgs Study Group of Escmid
• Organismes : Institut de Systématique, Evolution, Biodiversité Université Paris Sciences et Lettres Institut des Agents Infectieux [Lyon] Institut de Systématique, Evolution, Biodiversité Institut des Agents Infectieux [Lyon] Centre International de Recherche en Infectiologie Public Health England [London] Institut de Systématique, Evolution, Biodiversité Institut des Agents Infectieux [Lyon] Centre International de Recherche en Infectiologie Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Public Health England [London] Institut de Biologie Intégrative de la Cellule Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Hôpital de la Croix-Rousse [CHU - HCL] Public Health England [London] Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 Centre International de Recherche en Infectiologie Hôpital Femme Mère Enfant [CHU - HCL] Institut des Agents Infectieux [Lyon] Centre International de Recherche en Infectiologie
• Publié dans Nature Microbiology le 21/10/2020

---

Résumé : The multidrug-resistant Staphylococcus capitis NRCS-A clone is responsible for sepsis in preterm infants in neonatal intensive care units (NICUs) worldwide. Here, to retrace the spread of this clone and to identify drivers of its specific success, we investigated a representative collection of 250 S. capitis isolates from adults and newborns. Bayesian analyses confirmed the spread of the NRCS-A clone and enabled us to date its emergence in the late 1960s and its expansion during the 1980s, coinciding with the establishment of NICUs and the increasing use of vancomycin in these units, respectively. This dynamic was accompanied by the acquisition of mutations in antimicrobial resistance- and bacteriocin-encoding genes. Furthermore, combined statistical tools and a genome-wide association study convergently point to vancomycin resistance as a major driver of NRCS-A success. We also identified another S. capitis subclade (alpha clade) that emerged independently, showing parallel evolution towards NICU specialization and non-susceptibility to vancomycin, indicating convergent evolution in NICU-associated pathogens. These findings illustrate how the broad use of antibiotics can repeatedly lead initially commensal drug-susceptible bacteria to evolve into multidrug-resistant clones that are able to successfully spread worldwide and become pathogenic for highly vulnerable patients.

---

Fichiers liés : Wirth-NatGen-20-Niche specialization and spread of Staphylococcus capitis involved in neonatal sepsis.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 27/04/2020
• Auteurs : Luciano VidalCarina KampleitnerStéphanie KrissianMeadhbh Á BrennanOskar HoffmannYago RaymondYassine MaazouzMaria-Pau GinebraPhilippe RossetPierre Layrolle
• Organismes : Universität Wien = University of Vienna Sarcomes osseux et remodelage des tissus calcifiés - Phy-Os [Nantes - INSERM U1238] Hôpital Bretonneau Sarcomes osseux et remodelage des tissus calcifiés - Phy-Os [Nantes - INSERM U1238] Harvard University Universität Wien = University of Vienna Universitat Politècnica de Catalunya = Université polytechnique de Catalogne = Polytechnic University of Catalunya [Barcelona] Mimetis Biomaterials [Barcelone, Espagne] Universitat Politècnica de Catalunya = Université polytechnique de Catalogne = Polytechnic University of Catalunya [Barcelona] Mimetis Biomaterials [Barcelone, Espagne] Universitat Politècnica de Catalunya = Université polytechnique de Catalogne = Polytechnic University of Catalunya [Barcelona] Barcelona Institute of Science and Technology Sarcomes osseux et remodelage des tissus calcifiés - Phy-Os [Nantes - INSERM U1238] Hôpital Bretonneau Toulouse NeuroImaging Center
• Publié dans Scientific Reports le 26/10/2020

---

Résumé : Abstract Although autografts are considered to be the gold standard treatment for reconstruction of large bone defects resulting from trauma or diseases, donor site morbidity and limited availability restrict their use. Successful bone repair also depends on sufficient vascularization and to address this challenge, novel strategies focus on the development of vascularized biomaterial scaffolds. This pilot study aimed to investigate the feasibility of regenerating large bone defects in sheep using 3D-printed customized calcium phosphate scaffolds with or without surgical vascularization. Pre-operative computed tomography scans were performed to visualize the metatarsus and vasculature and to fabricate customized scaffolds and surgical guides by 3D printing. Critical-sized segmental defects created in the mid-diaphyseal region of the metatarsus were either left empty or treated with the 3D scaffold alone or in combination with an axial vascular pedicle. Bone regeneration was evaluated 1, 2 and 3 months post-implantation. After 3 months, the untreated defect remained non-bridged while the 3D scaffold guided bone regeneration. The presence of the vascular pedicle further enhanced bone formation. Histology confirmed bone growth inside the porous 3D scaffolds with or without vascular pedicle inclusion. Taken together, this pilot study demonstrated the feasibility of precised pre-surgical planning and reconstruction of large bone defects with 3D-printed personalized scaffolds.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 24/04/2020
• Auteurs : Charlotte Fox AlcoverGuillaume BernadatFaustin KabranPierre Le PogamKarine LeblancAlexander Fox RamosJean-François GallardElisabeth MourayPhilippe GrellierErwan PouponMehdi A Beniddir
• Organismes : Biomolécules : Conception, Isolement, Synthèse Biomolécules : Conception, Isolement, Synthèse Université Félix Houphouët-Boigny [Abidjan, Côte d'Ivoire] Laboratoire de Chimie Organique et Biologique Biomolécules : Conception, Isolement, Synthèse Biomolécules : Conception, Isolement, Synthèse Biomolécules : Conception, Isolement, Synthèse Institut de Chimie des Substances Naturelles Molécules de Communication et Adaptation des Micro-organismes Molécules de Communication et Adaptation des Micro-organismes Biomolécules : Conception, Isolement, Synthèse Biomolécules : Conception, Isolement, Synthèse
• Publié dans Journal of Natural Products le 28/10/2020

---

Résumé : Five new monoterpene indole alkaloids (1-5), including four serpentinine-related bisindoles and one alstonine derivative monomer, have been isolated from the aerial parts of Picralima nitida. Their structures were elucidated by analysis of their HRMS and NMR spectroscopic data, and their absolute configurations were deduced from the comparison of experimental and simulated ECD spectra. In addition, two known compounds (6 and 7), previously undescribed from P. nitida, have also been purified. The compound isolation workflow was guided by a molecular networking-based dereplication strategy. Twenty-three compounds were dereplicated from the EtOH extract of P. nitida and fractions network and were assigned various levels of identification confidence. The antiparasitic activities against Plasmodium falciparum as well as the cytotoxic activity against the MRC-5 cell line were determined for compounds 1-7.

---

Source

---

• Type de publi. : Autre publication
• Date de publi. : 21/04/2020
• Auteurs : Carlos Aguilar MelchorNicolas AragonMagali BardetSlim BettaiebLoïc BidouxOlivier BlazyJean-Christophe DeneuvillePhilippe GaboritAdrien HautevilleAyoub OtmaniOlivier RuattaJean-Pierre TillichGilles Zémor
• Organismes : Institut Supérieur de l'Aéronautique et de l'Espace Mathématiques & Sécurité de l'information Université de Rouen Normandie Worldline France Worldline France Mathématiques & Sécurité de l'information Ecole Nationale de l'Aviation Civile Mathématiques & Sécurité de l'information Mathématiques & Sécurité de l'information Université de Rouen Normandie Mathématiques & Sécurité de l'information Cryptologie symétrique, cryptologie fondée sur les codes et information quantique Institut de Mathématiques de Bordeaux

---

Résumé : ROLLO is a compilation of three candidates to NIST's competition for post-quantum cryptography standardization. They are based on rank metric codes and they share the same decryption algorithm for LRPC codes (see Sec.1). Rank-Ouroboros (formerly known as Ouroboros-R) and LAKE are IND-CPA KEM running in the category "post-quantum key exchange". LOCKER is an IND-CCA2 PKE running in the category "post-quantum public key encryption". Different sets of parameters for these three cryptosystems are proposed for security strength categories 1, 3, and 5. For clarification reasons, we have chosen to uniformize the name of our protocols. In

---

Fichiers liés : rollo-specification_2020-04-21.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 17/04/2020
• Auteurs : Athanase MillogoFayemendy PhilippeJean KaboréChristian NaponAnselme DabilgouMarie Paule Boncoeur-MartelPierre-Marie PreuxJean Yves SalleJean-Claude DesportPierre JésusJeoffray Diendéré
• Organismes : Neuroépidémiologie Tropicale Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale Service de Radiologie et Imagerie Médicale [CHU Limoges] Neuroépidémiologie Tropicale Service de l'Information Médicale et de l'Évaluation [CHU Limoges] Laboratoire de Biostatistique et d'Informatique Médicale Service de Médecine Physique et de Réadaptation [CHU Limoges] Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale Neuroépidémiologie Tropicale
• Publié dans Dysphagia le 01/11/2020

---

Résumé : Stroke frequently causes deglutition disorders, leading to a decline in nutritional status and complications, and increasing mortality. Sub-Saharan data are scarce. The objectives of this study were to assess complications and mortality among hospitalized patients in Burkina Faso during the first two weeks after stroke, and to investigate associated factors. Patients with stroke were followed prospectively in Ouagadougou and Bobo-Dioulasso hospitals. Deglutition disorders and nutritional parameters were assessed at baseline (D0) and on Days 8 (D8) and 14 (D14). Complications and mortality were recorded up to D14. Factors associated with complications and mortality were investigated using multivariate analysis. Of the 222 patients included, 81.5% developed at least one complication, and mortality was 17.1%. At D0, D8, and D14, the rate of deglutition disorders was 37.4%, 28.4%, and 15.8%, respectively, and that of undernourishment 25.2%, 29.4%, and 31.0%, respectively. In multivariate analysis, only the presence of deglutition disorders was a risk factor for developing at least one complication (OR = 5.47, 95% CI 1.81–16.51). Factors predicting death were the presence of deglutition disorders at D0 (OR = 7.19, 95% CI 3.10–16.66), and at least one seizure during follow-up (OR = 3.69, 95% CI 1.63–8.36). After stroke, the rates of complications, death, and undernourishment were high compared to Western countries. Prevention and management of deglutition disorders, and specific follow-up of patients with seizures could reduce post-stroke mortality.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 14/04/2020
• Auteurs : Cédric AnnweilerMélinda BeaudenonJennifer GautierRomain SimonVincent Dubée DubéeJustine GonsardElsa Parot-SchinkelAmal AidoudGuillaume AlbaretCédric AnnweilerAlexandra Audemard-VergerMarine AsfarJean BarréFlorian BerteauGaëlle BertolettiJean-Baptiste BeuscartAdrien BigotSophie BoucherElisabeth Botelho-NeversIsabelle Bourdel-MarchassonAnne Sophie BoureauAntoine BrangierCéline BrouessardMarie Laure BureauNoëlle CardinaudMichel CarlesKarine Castro-LionardThomas CelarierGuillaume ChapeletDavid ChirioEmilie ClabéPhilippe CodronJohan CourjonÉric CuaMarie Danet-LamasouAlexiane DecorbezMarine de la ChapelleElisa DemonchyEdouard DesvauxMonique D’hautefeuilleVincent DubéeGuillaume DuvalBertrand FougèrePaul GassieNicolas GiroultOlivier GuérinRégis HankardMarjorie HouvetStéphanie JobardCarole LacoutAurélie LafargueCécile Laubarie-MouretMaxime Le FlochSylvain Le GentilSébastien LléonartJocelyne LoisonRafaël MahieuFrançois MaillotLaure MartinezMarie MathieuAnthony MauclerePierre MénagerEmeline MichelThai Binh NguyenRomain OrdonezMarie OtekpoVirginie PichonFanny PoitauGary PommierValérie RabierKarine RissoHélène RivièreAgnès RouaudClaire Roubaud BaudronGuillaume SaccoFrédéric ScholastiqueEtienne Seronie-DoutriauxAchille TchallaWojciech TrzepizurYves-Marie Vandamme
• Organismes : Laboratoire de Psychologie des Pays de la Loire COVIT-TRIAL study group Centre Hospitalier Universitaire d'Angers COVIT-TRIAL study group Centre Hospitalier Universitaire d'Angers COVIT-TRIAL study group Centre Hospitalier Universitaire d'Angers COVIT-TRIAL study group CHU Saint-Antoine [AP-HP] Sorbonne Université COVIT-TRIAL study group Centre de Recherche en Cancérologie et Immunologie Nantes-Angers COVIT-TRIAL study group Centre Hospitalier Universitaire d'Angers COVIT-TRIAL study group Centre Hospitalier Régional Universitaire de Tours COVIT-TRIAL study group Pôle de Gérontologie Clinique Bordeaux Research In Translational Oncology [Bordeaux] COVIT-TRIAL study group Laboratoire de Psychologie des Pays de la Loire COVIT-TRIAL study group Service de médecine interne [CHU Caen] COVIT-TRIAL study group Centre Hospitalier Universitaire d'Angers COVIT-TRIAL study group COVIT-TRIAL study group CHU d'Angers Hôpital de la Cavale Blanche - CHRU Brest COVIT-TRIAL study group COVIT-TRIAL study group Evaluation des technologies de santé et des pratiques médicales - ULR 2694 COVIT-TRIAL study group Centre Hospitalier Régional Universitaire de Tours COVIT-TRIAL study group ED 515 - Complexité du vivant Centre Hospitalier Universitaire d'Angers Université d'Angers COVIT-TRIAL study group Groupe Immunité des Muqueuses et Agents Pathogènes COVIT-TRIAL study group Bordeaux population health COVIT-TRIAL study group COVIT-TRIAL study group Laboratoire de Psychologie des Pays de la Loire COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group CHU Limoges COVIT-TRIAL study group CHU Pointe-à-Pitre / Abymes [Guadeloupe] Université des Antilles Centre méditerranéen de médecine moléculaire COVIT-TRIAL study group COVIT-TRIAL study group Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] COVIT-TRIAL study group Université d'Angers COVIT-TRIAL study group Service d'infectiologie [CHU Nice] COVIT-TRIAL study group Université de Bordeaux COVIT-TRIAL study group MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale COVIT-TRIAL study group Centre méditerranéen de médecine moléculaire COVIT-TRIAL study group Service d'infectiologie [CHU Nice] COVIT-TRIAL study group Centre de résonance magnétique des systèmes biologiques COVIT-TRIAL study group Université Nice Sophia Antipolis - Faculté de Médecine COVIT-TRIAL study group COVIT-TRIAL study group Université Nice Sophia Antipolis - Faculté de Médecine COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group CHU Saint-Antoine [AP-HP] Sorbonne Université COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group COVIT-TRIAL study group
• Publié dans Trials le 31/10/2020

---

Résumé : Abstract Background With the lack of effective therapy, chemoprevention, and vaccination against SARS-CoV-2, focusing on the immediate repurposing of existing drugs gives hope of curbing the COVID-19 pandemic. A recent unbiased genomics-guided tracing of the SARS-CoV-2 targets in human cells identified vitamin D among the three top-scoring molecules manifesting potential infection mitigation patterns. Growing pre-clinical and epidemiological observational data support this assumption. We hypothesized that vitamin D supplementation may improve the prognosis of COVID-19. The aim of this trial is to compare the effect of a single oral high dose of cholecalciferol versus a single oral standard dose on all-cause 14-day mortality rate in COVID-19 older adults at higher risk of worsening. Methods The COVIT-TRIAL study is an open-label, multicenter, randomized controlled superiority trial. Patients aged ≥ 65 years with COVID-19 (diagnosed within the preceding 3 days with RT-PCR and/or chest CT scan) and at least one worsening risk factor at the time of inclusion (i.e., age ≥ 75 years, or SpO2 ≤ 94% in room air, or PaO2/FiO2 ≤ 300 mmHg), having no contraindications to vitamin D supplementation, and having received no vitamin D supplementation > 800 IU/day during the preceding month are recruited. Participants are randomized either to high-dose cholecalciferol (two 200,000 IU drinking vials at once on the day of inclusion) or to standard-dose cholecalciferol (one 50,000 IU drinking vial on the day of inclusion). Two hundred sixty participants are recruited and followed up for 28 days. The primary outcome measure is all-cause mortality within 14 days of inclusion. Secondary outcomes are the score changes on the World Health Organization Ordinal Scale for Clinical Improvement (OSCI) scale for COVID-19, and the between-group comparison of safety. These outcomes are assessed at baseline, day 14, and day 28, together with the serum concentrations of 25(OH)D, creatinine, calcium, and albumin at baseline and day 7. Discussion COVIT-TRIAL is to our knowledge the first randomized controlled trial testing the effect of vitamin D supplementation on the prognosis of COVID-19 in high-risk older patients. High-dose vitamin D supplementation may be an effective, well-tolerated, and easily and immediately accessible treatment for COVID-19, the incidence of which increases dramatically and for which there are currently no scientifically validated treatments. Trial registration ClinicalTrials.gov NCT04344041 . Registered on 14 April 2020 Trial status Recruiting. Recruitment is expected to be completed in April 2021.

---

Fichiers liés : 13063_2020_Article_4928.pdf

---

Source

---

• Type de publi. : Ouvrage (y compris édition critique et traduction)
• Date de publi. : 10/04/2020
• Auteurs : Samuel van WilligenMaxence BaillyBrigitte RöderAurore SchmittAndré d'AnnaFerran AntolínMartin BaderJacques Élie BrochierCharlène DelefosseAnthony DenaireMichel ErreraFranziska FollmannJean-Jouis GuendonFrançois GuyonnetBoris HélardStefanie JacometAna JesusMarlu KühnThibault LachenalHector Martínez-GrauPierre PétrequinYoann QuesnelPhilippe RentzelAdrien ReggioMarguerita SchäferWerner H SchochMaeva SeryesL. Viel
• Organismes : Laboratoire méditerranéen de préhistoire Europe-Afrique Laboratoire méditerranéen de préhistoire Europe-Afrique Laboratoire méditerranéen de préhistoire Europe-Afrique Laboratoire méditerranéen de préhistoire Europe-Afrique Laboratoire méditerranéen de préhistoire Europe-Afrique Aix Marseille Université Laboratoire méditerranéen de préhistoire Europe-Afrique Aix Marseille Université

---

Source